WAVE LIFE SCIENCES LTD. Payments for (Proceeds from) Tenant Allowance
WAVE LIFE SCIENCES LTD. (WVE) reported Payments for (Proceeds from) Tenant Allowance of $4.30 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromTenantAllowance · last filed 2018-11-09
- WAVE LIFE SCIENCES LTD. payments for (proceeds from) tenant allowance for the quarter ending 2018-09-30 was $628.00K.
- WAVE LIFE SCIENCES LTD. payments for (proceeds from) tenant allowance for the quarter ending 2018-06-30 was $2.40M.
- WAVE LIFE SCIENCES LTD. payments for (proceeds from) tenant allowance for the quarter ending 2018-03-31 was $1.28M.
- WAVE LIFE SCIENCES LTD. payments for (proceeds from) tenant allowance for fiscal 2017 was $745.00K.
| Period end | Payments for (Proceeds from) Tenant Allowance 3 month | Payments for (Proceeds from) Tenant Allowance 6 month | Payments for (Proceeds from) Tenant Allowance 9 month | Payments for (Proceeds from) Tenant Allowance 12 month |
|---|---|---|---|---|
| 2018-09-30 | $628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $3.02M derived: sum of 2 quarters · filed 2018-11-09 | $4.30M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $3.67M 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | $1.28M 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $745.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |